Mutual of America Capital Management LLC Makes New $321,000 Investment in Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE)

Mutual of America Capital Management LLC bought a new position in shares of Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) during the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor bought 5,780 shares of the biopharmaceutical company’s stock, valued at approximately $321,000.

Other hedge funds have also recently bought and sold shares of the company. Frazier Life Sciences Management L.P. acquired a new position in Ultragenyx Pharmaceutical during the second quarter worth $17,468,000. Teachers Retirement System of The State of Kentucky acquired a new stake in shares of Ultragenyx Pharmaceutical in the first quarter valued at about $691,000. Candriam S.C.A. grew its position in shares of Ultragenyx Pharmaceutical by 33.1% in the second quarter. Candriam S.C.A. now owns 688,942 shares of the biopharmaceutical company’s stock valued at $28,314,000 after purchasing an additional 171,345 shares during the last quarter. Hennion & Walsh Asset Management Inc. grew its position in shares of Ultragenyx Pharmaceutical by 47.9% in the second quarter. Hennion & Walsh Asset Management Inc. now owns 73,289 shares of the biopharmaceutical company’s stock valued at $3,012,000 after purchasing an additional 23,752 shares during the last quarter. Finally, Clearline Capital LP acquired a new stake in shares of Ultragenyx Pharmaceutical in the second quarter valued at about $1,355,000. 97.67% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, CFO Howard Horn sold 7,465 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Thursday, October 10th. The shares were sold at an average price of $52.76, for a total value of $393,853.40. Following the completion of the transaction, the chief financial officer now owns 92,301 shares in the company, valued at approximately $4,869,800.76. The trade was a 7.48 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Emil D. Kakkis sold 20,000 shares of Ultragenyx Pharmaceutical stock in a transaction that occurred on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the transaction, the chief executive officer now owns 2,223,985 shares of the company’s stock, valued at $124,209,562.25. This trade represents a 0.89 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 27,556 shares of company stock worth $1,515,967 over the last quarter. Company insiders own 5.80% of the company’s stock.

Ultragenyx Pharmaceutical Stock Up 1.6 %

Shares of RARE opened at $48.13 on Friday. The stock has a market cap of $4.44 billion, a price-to-earnings ratio of -7.44 and a beta of 0.58. Ultragenyx Pharmaceutical Inc. has a 12 month low of $37.02 and a 12 month high of $60.37. The company has a 50-day moving average price of $52.48 and a two-hundred day moving average price of $48.57.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, topping analysts’ consensus estimates of ($1.45) by $0.05. The firm had revenue of $139.49 million during the quarter, compared to analysts’ expectations of $135.28 million. Ultragenyx Pharmaceutical had a negative net margin of 106.93% and a negative return on equity of 187.12%. The company’s revenue for the quarter was up 42.3% compared to the same quarter last year. During the same quarter last year, the company earned ($2.23) earnings per share. Equities research analysts expect that Ultragenyx Pharmaceutical Inc. will post -6.2 EPS for the current fiscal year.

Analysts Set New Price Targets

RARE has been the topic of several research analyst reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday, November 6th. TD Cowen raised their price target on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Canaccord Genuity Group reaffirmed a “buy” rating and issued a $121.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Tuesday, November 12th. Barclays lowered their price target on Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating on the stock in a research report on Monday, August 5th. Finally, The Goldman Sachs Group increased their target price on shares of Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the company a “buy” rating in a research note on Friday, August 2nd. Two analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $87.46.

Ultragenyx Pharmaceutical Profile

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.